In the 2026 China PIII, CSPC Group ranked 8th in Innovation and 2nd in Invention. As an innovation-driven, integrated pharmaceutical company spanning R&D, manufacturing and commercialization, CSPC continues to pursue its dual-engine strategy of "innovation and internationalization." In 2025, the company was characterized by a deepening R&D system and upgraded international collaboration, with innovation capabilities further strengthening its high-quality pipeline and global development reach.

CSPC's most distinctive strength in 2025 was the translation of high R&D intensity into a deep late-stage pipeline. In 2025, the company's full-year R&D expenses reached RMB 5.809 billion, up 11.9% YoY and representing approximately 28.2% of revenue from its finished drug business. Sustained investment enables CSPC to advance candidates across multiple technology directions and development stages simultaneously...

Download the report to see the full company profile.